Dear Editor,

It is known that microRNA *let-7a* can be useful for diagnosis and therapy of cancer, including prostate cancer (PCa).[@ref1] A recent article by Wang *et al*.[@ref2] comprehensively showed that *let-7a*1 could inhibit the expression of insulin-like growth factor-1 receptor (IGF1R) by directly targeting the T1 and T2 sites in the 3' untranslated region (3'UTR) of IGF1R mRNA. Furthermore, they found that *let-7a*1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of PC-3 cell proliferation, cell cycle arrest and induced apoptosis and that inhibition of *let-7a*1 could up-regulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation.[@ref2] Their study is interesting and provides valuable data on the role of *let-7a* in PCa. Another study has[@ref3], in fact, demonstrated that *let-7a* directly bound to the 3'UTR of E2F2 (E2F family of transcription factor) and CCND2 (cyclin D2) and downregulated their expression, leading to cell-cycle arrest at the G~1~/S phase and inhibit the PC-3 cells and LNCaP cells growth, especially in hormone-refractory PCa. In addition, xenograft models of PC-3 cells confirmed the capability of *let-7a* to inhibit prostate tumor development *in vivo*.[@ref3] Emerging evidences suggest that the let-7 family plays a crucial role in the progression of PCa by maintaining and regulating molecular features of cancer stem cells or cancer stem-like cells in PCa.[@ref4][@ref5] Recently, Liu *et al*.[@ref6] showed that *let-7a* was underexpressed in the purified CD44 + Du145, LAPC9 and LAPC4 cells. And after they infected Du145 and LAPC9 cells with pLL3.7-*let-7a*, both Du145 clonal development and sphere formation were inhibited. Impressively, the continuously delivered *let-7a* distinctly slowed tumor growth and inhibited tumor regeneration of LAPC9 cells. However, PCa cells infected with pLL3.7-*let-7a* keep low steady-state levels of *let-7a*. This phenomenon may be explained by *let-7a* miRNAs, which have a fast turnover rate. Another interesting finding was that *let-7a* caused a prominent G2/M phase arrest without inducing senescence.[@ref6] What\'s more, Kong and colleagues indicated that loss of let-7 family with corresponding overexpression of enhancer of zeste homolog 2 (EZH2) contributed to human PCa aggressiveness, which could be attenuated after the formulated 3,3'-diindolylmethane (BR-DIM) invention in their ongoing phase II clinical trial in patients prior to radical prostatectomy.[@ref7]

The above-described results demonstrate a genetic association between *let-7a* and PCa, supporting a potential role for *let-7a* in human PCa. A recent study showed that *let-7a* remained to significantly discriminate normal tissues from PCa patients from those of the cancer negative control group with elevated prostate-specific antigen levels (*P* \< 0.05).[@ref8] In any case, reduced transcription patterns of *let-7a* could be considered as indicators of occult tumors in the vicinity. Furthermore, Schubert *et al*.[@ref9] also confirmed a significant downregulation of *let-7a* in the high-risk PCa cases compared to benign prostatic hyperplasia (*P* \< 0.001). However, Pesta *et al*.[@ref10] found no statistical differences in expression of *let-7a* in the PCa tissue samples in comparison with the BPH tissue samples. They have reminded us that the behavior of BPH did not necessarily correspond with that of normal prostatic tissue.[@ref10]

In summary, available evidence suggests a key role for *let-7a* in the development of PCa although there are differences in the samples; moreover, several target genes of *let-7a* are associated with PCa (**[Table 1](#T1){ref-type="table"}**). Thus, these findings indicate that *let-7a* may be a potential noninvasive biomarker and novel therapeutic candidate in PCa. However, the precise mechanisms of *let-7a* in the pathogenesis of PCa need to be elucidated. Conclusions drawn from animal model studies should be limited to animal models until they are confirmed in human PCa. Therefore, further studies are required, especially in human systems, to comprehensively explore the therapeutic potential of *let-7a* in PCa. The development of therapeutic agents about *let-7a* could result in important new innovative therapies for the treatment of PCa and other cancers.
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